Format

Send to

Choose Destination
J Biosci. 2017 Mar;42(1):161-173.

Immune modulation by dendritic-cell-based cancer vaccines.

Author information

1
APAC Biotech Pvt Ltd, Gurgaon, India, chaitanya@apacbiotech.com.

Abstract

The interplay between host immunity and tumour cells has opened the possibility of targeting tumour cells by modulation of the human immune system. Cancer immunotherapy involves the treatment of a tumour by utilizing the recombinant human immune system components to target the pro-tumour microenvironment or by revitalizing the immune system with the ability to kill tumour cells by priming the immune cells with tumour antigens. In this review, current immunotherapy approaches to cancer with special focus on dendritic cell (DC)-based cancer vaccines are discussed. Some of the DC-based vaccines under clinical trials for various cancer types are highlighted. Establishing tumour immunity involves a plethora of immune components and pathways; hence, combining chemotherapy, radiation therapy and various arms of immunotherapy, after analysing the benefits of individual therapeutic agents, might be beneficial to the patient.

PMID:
28229976
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Indian Academy of Sciences
Loading ...
Support Center